Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction
- 5 April 2012
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (5) , 717-726
Abstract
AIMS beta-adrenoceptor blockers are avoided in asthma due to concerns of bronchoconstriction. We investigated the safety of acute exposure to propranolol in asthmatics, sequentially challenged with histamine to mimic an asthma exacerbation and evaluated the role of intravenous hydrocortisone in potentiating salbutamol reversibility. METHODS Persistent atopic asthmatics, requiring <= 1000 mg day(-1) budesonide, performed a randomized double-blind placebo-controlled crossover study. Following 10 mg or 20 mg of oral propranolol, patients received 400 mg intravenous hydrocortisone or placebo, followed by histamine challenge with nebulized salbutamol 5mg and ipratropium 500 mg recovery. RESULTS Thirteen patients completed per protocol. Hydrocortisone did not potentiate salbutamol recovery post propranolol and histamine challenge vs. placebo (mean difference in FEV1 0.04 ml, 95% CI -0.07, 0.15, P = 0.417). beta-adrenoceptor blocker induced bronchoconstriction was demonstrated by spirometry and impulse oscillometry. For the placebo visit, FEV1 fell 4.7% 2 hours post propranolol (95% CI 1.8, 7.5, P = 0.008) whilst total airway resistance (R5%) increased 31.3% (95% CI 15.6, 47.0, P = 0.04). On both visits FEV1% and R5% returned to baseline after salbutamol post histamine. CONCLUSION Nebulized salbutamol and ipratropium produced a full recovery after propranolol and histamine induced bronchoconstriction, independent of hydrocortisone use. Since the greatest risk of beta-adrenoceptor blockade is after first dose, our findings offer reassurance to those undertaking further evaluation of chronic beta-adrenoceptor blockade as a potential treatment for mild-to-moderate asthma.Keywords
This publication has 28 references indexed in Scilit:
- Response to salbutamol in patients with mild asthma treated with nadololEuropean Respiratory Journal, 2010
- β2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine modelProceedings of the National Academy of Sciences, 2009
- The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot studyPulmonary Pharmacology & Therapeutics, 2008
- Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma modelPulmonary Pharmacology & Therapeutics, 2008
- The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptorsBritish Journal of Pharmacology, 2005
- PROPRANOLOL INCREASES REDUCED BETA-RECEPTOR FUNCTION IN SEVERELY ANXIOUS PATIENTSThe Lancet, 1983
- BETA-BLOCKING DRUGS INCREASE RESPONSIVENESS TO PROSTACYCLIN IN HYPERTENSIVE PATIENTSThe Lancet, 1982
- Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.BMJ, 1981
- Severe asthma after inadvertent ingestion of oxprenolol.Thorax, 1980
- EFFECT OF A β-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICSThe Lancet, 1964